KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Sales (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Sales for 16 consecutive years, with 0.31% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 77.0% to 0.31% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.23% through Dec 2025, down 21.0% year-over-year, with the annual reading at 0.23% for FY2025, 21.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.31% at Halozyme Therapeutics, down from 0.49% in the prior quarter.
  • The five-year high for Return on Sales was 1.87% in Q3 2021, with the low at 0.31% in Q4 2025.
  • Average Return on Sales over 5 years is 0.45%, with a median of 0.4% recorded in 2024.
  • The sharpest move saw Return on Sales soared 132bps in 2021, then crashed -157bps in 2022.
  • Over 5 years, Return on Sales stood at 0.65% in 2021, then plummeted by -51bps to 0.32% in 2022, then increased by 17bps to 0.37% in 2023, then increased by 24bps to 0.46% in 2024, then tumbled by -168bps to 0.31% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.31%, 0.49%, and 0.51% for Q4 2025, Q3 2025, and Q2 2025 respectively.